The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Abstract
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group defined what needs to be considered as 'non-valvular AF' and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 15 topics are (i) practical start-up and follow-up scheme for patients on NOACs; (ii) how to measure the anticoagulant effect of NOACs; (iii) drug-drug interactions and pharmacokinetics of NOACs; (iv) switching between anticoagulant regimens; (v) ensuring adherence of NOAC intake; (vi) how to deal with dosing errors; (vii) patients with chronic kidney disease; (viii) what to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a risk of bleeding?; (xi) management of bleeding complications; (x) patients undergoing a planned surgical intervention or ablation; (xi) patients undergoing an urgent surgical intervention; (xii) patients with AF and coronary artery disease; (xiii) cardioversion in a NOAC-treated patient; (xiv) patients presenting with acute stroke while on NOACs; and (xv) NOACs vs. VKAs in AF patients with a malignancy. Additional information and downloads of the text and anticoagulation cards in >16 languages can be found on an European Heart Rhythm Association web site (www.NOACforAF.eu).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationApixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citationStent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
Saver, J. L., Goyal, M., Bonafe, A., Diener, H.-C., Levy, E. I., Pereira, V. M., Albers, G. W., Cognard, C., Cohen, D. J., Hacke, W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415061 · Cited by 5,193
Self-citationEdoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
Jovin, T. G., Chamorro, A., Cobo, E., de Miquel, M. A., Molina, C. A., Rovira, A., San Román, L., Serena, J., Abilleira, S., Ribó, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503780 · Cited by 4,898
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citationHemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citationAuthors/Task Force Members, Hamm, C. W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,080
Cappato, R., Calkins, H., Chen, S.-A., Davies, W., Iesaka, Y., Kalman, J., Kim, Y.-H., Klein, G., Natale, A., Packer, D., et al. (2010) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.109.859116 · Cited by 2,852
Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S.-A., Crijns, H. J. G., Damiano, R. J., Davies, D. W., DiMarco, J., et al. (2012) · Europace · doi:10.1093/europace/eus027 · Cited by 2,722
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone, G. W., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Kornowski, R., Hartmann, F., Gersh, B. J., Pocock, S. J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708191 · Cited by 1,867
Guidelines for the management of atrial fibrillation
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,747
Self-citationDewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719
Fox, K. A. A., Dabbous, O. H., Goldberg, R. J., Pieper, K. S., Eagle, K. A., Van de Werf, F., Avezum, Á., Goodman, S. G., Flather, M. D., Anderson, F. A., et al. (2006) · BMJ · doi:10.1136/bmj.38985.646481.55 · Cited by 1,693
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Self-citationDabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Morgenstern, L. B., Hemphill, J. C., Anderson, C., Becker, K., Broderick, J. P., Connolly, E. S., Greenberg, S. M., Huang, J. N., Macdonald, R. L., Messé, S. R., et al. (2010) · Stroke · doi:10.1161/str.0b013e3181ec611b · Cited by 1,496
Bivalirudin for Patients with Acute Coronary Syndromes
Stone, G. W., McLaurin, B. T., Cox, D. A., Bertrand, M. E., Lincoff, A. M., Moses, J. W., White, H. D., Pocock, S. J., Ware, J. H., Feit, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062437 · Cited by 1,459
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Friberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,167
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Olesen, J. B., Lip, G. Y. H., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H., & Torp-Pedersen, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105594 · Cited by 930
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Reilly, P. A., Lehr, T., Haertter, S., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Ezekowitz, M. D., Nehmiz, G., Wang, S., & Wallentin, L. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.104 · Cited by 834
Steiner, T., Salman, R. A.-S., Beer, R., Christensen, H., Cordonnier, C., Csiba, L., Forsting, M., Harnof, S., Klijn, C. J. M., Krieger, D., et al. (2014) · International Journal of Stroke · doi:10.1111/ijs.12309 · Cited by 813
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Self-citationStangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis
Poon, M. T. C., Fonville, A. F., & Al-Shahi Salman, R. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306476 · Cited by 653
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
Gyurkocza, B., & Sandmaier, B. M. (2014) · Blood · doi:10.1182/blood-2014-02-514778 · Cited by 614
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D., Chen, S., Bonacorsi, S., Wong, P. C., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 612
Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608
Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation
Birnie, D. H., Healey, J. S., Wells, G. A., Verma, A., Tang, A. S., Krahn, A. D., Simpson, C. S., Ayala-Paredes, F., Coutu, B., Leiria, T. L. L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302946 · Cited by 579
Sørensen, R., Hansen, M. L., Abildstrom, S. Z., Hvelplund, A., Andersson, C., Jørgensen, C., Madsen, J. K., Hansen, P. R., Køber, L., Torp-Pedersen, C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61751-7 · Cited by 575
Hohnloser, S. H., Hijazi, Z., Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., Keltai, M., Lanas, F., Lopes, R. D., Lopez-Sendon, J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs274 · Cited by 574
Kuramatsu, J. B., Gerner, S. T., Schellinger, P. D., Glahn, J., Endres, M., Sobesky, J., Flechsenhar, J., Neugebauer, H., Jüttler, E., Grau, A., et al. (2015) · JAMA · doi:10.1001/jama.2015.0846 · Cited by 568
Task Force Members, Lip, G. Y. H., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J. M., Haeusler, K. G., Boriani, G., Capodanno, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu298 · Cited by 566
Self-citationPrins, M. H., Lensing, A. W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Raskob, G. E., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-21 · Cited by 551
Shahzad, A., Kemp, I., Mars, C., Wilson, K., Roome, C., Cooper, R., Andron, M., Appleby, C., Fisher, M., Khand, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60924-7 · Cited by 543
Healey, J. S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., Themeles, E., Heidbuchel, H., Avezum, A., Reilly, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.090464 · Cited by 541
Self-citationOldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Self-citationTaylor, D. W., Barnett, H. J., Haynes, R. B., Ferguson, G. G., Sackett, D. L., Thorpe, K. E., Simard, D., Silver, F. L., Hachinski, V., Clagett, G. P., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05388-x · Cited by 530
Nagarakanti, R., Ezekowitz, M. D., Oldgren, J., Yang, S., Chernick, M., Aikens, T. H., Flaker, G., Brugada, J., Kamenský, G., Parekh, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.977546 · Cited by 526
Self-citationPiccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Lokhnygina, Y., Go, A. S., Patel, M. R., Mahaffey, K. W., Halperin, J. L., Breithardt, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.107128 · Cited by 502
Self-citationMarlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Romero-Ortuno, R., Walsh, C. D., Lawlor, B. A., & Kenny, R. A. (2010) · BMC Geriatrics · doi:10.1186/1471-2318-10-57 · Cited by 494
Di Biase, L., Burkhardt, J. D., Santangeli, P., Mohanty, P., Sanchez, J. E., Horton, R., Gallinghouse, G. J., Themistoclakis, S., Rossillo, A., Lakkireddy, D., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.006426 · Cited by 485
Dans, A. L., Connolly, S. J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., Ezekowitz, M., Oldgren, J., Eikelboom, J. W., Reilly, P. A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.115386 · Cited by 484
Self-citationApostolakis, S., Sullivan, R. M., Olshansky, B., & Lip, G. Y. H. (2013) · Chest · doi:10.1378/chest.13-0054 · Cited by 482
Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.042 · Cited by 480
Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009351883 · Cited by 453
Fiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., Hoppmann, P., Schneider, S., Fusaro, M., Ott, I., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.050 · Cited by 443
Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T., & Bruck, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03753.x · Cited by 432
Uchino, K. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1666 · Cited by 431
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv177 · Cited by 422
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Ansell, J. E., Bakhru, S. H., Laulicht, B. E., Steiner, S. S., Grosso, M., Brown, K., Dishy, V., Noveck, R. J., & Costin, J. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1411800 · Cited by 419
Blaschke, T. F., Osterberg, L., Vrijens, B., & Urquhart, J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011711-113247 · Cited by 419
Lamberts, M., Olesen, J. B., Ruwald, M. H., Hansen, C. M., Karasoy, D., Kristensen, S. L., Køber, L., Torp-Pedersen, C., Gislason, G. H., & Hansen, M. L. (2012) · Circulation · doi:10.1161/circulationaha.112.114967 · Cited by 413
Hendriks, J. M. L., de Wit, R., Crijns, H. J. G. M., Vrijhoef, H. J. M., Prins, M. H., Pisters, R., Pison, L. A. F. G., Blaauw, Y., & Tieleman, R. G. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs071 · Cited by 409
Beyer-Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C., Werth, S., Sahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 407
Hart, R. G., Diener, H.-C., Yang, S., Connolly, S. J., Wallentin, L., Reilly, P. A., Ezekowitz, M. D., & Yusuf, S. (2012) · Stroke · doi:10.1161/strokeaha.112.650614 · Cited by 406
Self-citationRuff, C. T., Giugliano, R. P., Braunwald, E., Morrow, D. A., Murphy, S. A., Kuder, J. F., Deenadayalu, N., Jarolim, P., Betcher, J., Shi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61943-7 · Cited by 405
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht134 · Cited by 405
Self-citationLarsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K. M., Callréus, T., Rosenzweig, M., & Lip, G. Y. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.020 · Cited by 403
Hijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.003628 · Cited by 396
Self-citationAlexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.972323 · Cited by 396
Baudo, F., Collins, P., Huth-Kühne, A., Lévesque, H., Marco, P., Nemes, L., Pellegrini, F., Tengborn, L., & Knoebl, P. (2012) · Blood · doi:10.1182/blood-2012-02-408930 · Cited by 386
Beyer-Westendorf, J., Gelbricht, V., Forster, K., Ebertz, F., Kohler, C., Werth, S., Kuhlisch, E., Stange, T., Thieme, C., Daschkow, K., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht557 · Cited by 383
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Cappato, R., Ezekowitz, M. D., Klein, A. L., Camm, A. J., Ma, C.-S., Le Heuzey, J.-Y., Talajic, M., Scanavacca, M., Vardas, P. E., Kirchhof, P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu367 · Cited by 372
Self-citationMueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vanga, S. R., Santangeli, P., Swarup, V., Pimentel, R., Mansour, M. C., D'Avila, A., Sanchez, J. E., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.014 · Cited by 356
Hohnloser, S. H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Eikelboom, J., Brueckmann, M., Yusuf, S., & Connolly, S. J. (2012) · Circulation · doi:10.1161/circulationaha.111.055970 · Cited by 348
Self-citationMajor Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Hylek, E. M., Held, C., Alexander, J. H., Lopes, R. D., De Caterina, R., Wojdyla, D. M., Huber, K., Jansky, P., Steg, P. G., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.549 · Cited by 344
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
Mueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
Chan, K. E., Edelman, E. R., Wenger, J. B., Thadhani, R. I., & Maddux, F. W. (2015) · Circulation · doi:10.1161/circulationaha.114.014113 · Cited by 325
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J., & Veltkamp, R. (2011) · Stroke · doi:10.1161/strokeaha.111.624650 · Cited by 324
Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., Lang, B., Ramael, S., Moschetti, V., Gruenenfelder, F., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60732-2 · Cited by 319
Marchesi, C., Pierfranceschi, M., Crowther, M., Garcia, D., Hylek, E., Witt, D., Clark, N., Squizzato, A., Imberti, D., Ageno, W., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0052 · Cited by 306
LIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
(1997) · The Lancet · doi:10.1016/s0140-6736(97)01180-x · Cited by 301
FURUGOHRI, T., ISOBE, K., HONDA, Y., KAMISATO‐MATSUMOTO, C., SUGIYAMA, N., NAGAHARA, T., MORISHIMA, Y., & SHIBANO, T. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03064.x · Cited by 301
Cardiology Patient Page: Warning Signs of a Heart Attack
Ornato, J. P., & Hand, M. M. (2001) · Circulation · doi:10.1161/01.cir.103.25.e124 · Cited by 292
Stroke prevention in atrial fibrillation: An Asian perspective
Wang, K.-L., Lip, G. Y. H., & Chiang, C.-E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0948 · Cited by 287
Wang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
Bonde, A. N., Lip, G. Y. H., Kamper, A.-L., Hansen, P. R., Lamberts, M., Hommel, K., Hansen, M. L., Gislason, G. H., Torp-Pedersen, C., & Olesen, J. B. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.051 · Cited by 285
Lamberts, M., Gislason, G. H., Lip, G. Y. H., Lassen, J. F., Olesen, J. B., Mikkelsen, A. P., Sørensen, R., Køber, L., Torp-Pedersen, C., & Hansen, M. L. (2014) · Circulation · doi:10.1161/circulationaha.113.004834 · Cited by 284
Winkelmayer, W. C., Liu, J., Setoguchi, S., & Choudhry, N. K. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04550511 · Cited by 280
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Mehta, S. R., Granger, C. B., Eikelboom, J. W., Bassand, J.-P., Wallentin, L., Faxon, D. P., Peters, R. J. G., Budaj, A., Afzal, R., Chrolavicius, S., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.042 · Cited by 266
Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., Hankey, G. J., Hacke, W., Becker, R. C., Nessel, C. C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.025 · Cited by 266
Self-citationNielsen, P. B., Larsen, T. B., Skjøth, F., Gorst-Rasmussen, A., Rasmussen, L. H., & Lip, G. Y. H. (2015) · Circulation · doi:10.1161/circulationaha.115.015735 · Cited by 265
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
De Caterina, R., Husted, S., Wallentin, L., De Caterina, R., Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.008 · Cited by 265
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286904 · Cited by 254
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
Zahir, H., Brown, K. S., Vandell, A. G., Desai, M., Maa, J.-F., Dishy, V., Lomeli, B., Feussner, A., Feng, W., He, L., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013445 · Cited by 252
Puwanant, S., Varr, B. C., Shrestha, K., Hussain, S. K., Tang, W. H. W., Gabriel, R. S., Wazni, O. M., Bhargava, M., Saliba, W. I., Thomas, J. D., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.037 · Cited by 250
Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.004 · Cited by 248
Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.-M., Emmerich, J., Marchand-Leroux, C., Lecompte, T., & Samama, C.-M. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318238c036 · Cited by 246
Avezum, A., Lopes, R. D., Schulte, P. J., Lanas, F., Gersh, B. J., Hanna, M., Pais, P., Erol, C., Diaz, R., Bahit, M. C., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.014807 · Cited by 243
Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation
Flaker, G., Lopes, R. D., Al-Khatib, S. M., Hermosillo, A. G., Hohnloser, S. H., Tinga, B., Zhu, J., Mohan, P., Garcia, D., Bartunek, J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.062 · Cited by 239
Fiore, L. D., Ezekowitz, M. D., Brophy, M. T., Lu, D., Sacco, J., & Peduzzi, P. (2002) · Circulation · doi:10.1161/hc0502.103329 · Cited by 224
Mendell, J., Zahir, H., Matsushima, N., Noveck, R., Lee, F., Chen, S., Zhang, G., & Shi, M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0029-0 · Cited by 223
Lip, G. Y. H., Diener, H.-C., Brueckmann, M., van Ryn, J., Clemens, A., & Huisman, M. V. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0718 · Cited by 218
Self-citationIn Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180240 · Cited by 216
Hanley, J. P. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.008904 · Cited by 215
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
Chatelain, C., Chatelain, B., Douxfils, J., Dogné, J.-M., & Mullier, F. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0898 · Cited by 213
Warkentin, T. E., Margetts, P., Connolly, S. J., Lamy, A., Ricci, C., & Eikelboom, J. W. (2012) · Blood · doi:10.1182/blood-2011-11-393587 · Cited by 207
Warfarin in atrial fibrillation patients with moderate chronic kidney disease
Hart, R. G., Pearce, L. A., Asinger, R. W., & Herzog, C. A. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02400311 · Cited by 204
Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., & Sundstrom, J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht049 · Cited by 198
Self-citationSticherling, C., Marin, F., Birnie, D., Boriani, G., Calkins, H., Dan, G.-A., Gulizia, M., Halvorsen, S., Hindricks, G., Kuck, K.-H., et al. (2015) · EP Europace · doi:10.1093/europace/euv190 · Cited by 197
Self-citationBreithardt, G., Baumgartner, H., Berkowitz, S. D., Hellkamp, A. S., Piccini, J. P., Stevens, S. R., Lokhnygina, Y., Patel, M. R., Halperin, J. L., Singer, D. E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu305 · Cited by 196
Self-citationSevere Renal Impairment and Stroke Prevention in Atrial Fibrillation
Marinigh, R., Lane, D. A., & Lip, G. Y. H. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.013 · Cited by 195
Lopes, R. D., Pieper, K. S., Horton, J. R., Al-Khatib, S. M., Newby, L. K., Mehta, R. H., Van de Werf, F., Armstrong, P. W., Mahaffey, K. W., Harrington, R. A., et al. (2008) · Heart · doi:10.1136/hrt.2007.134486 · Cited by 188
Incidence and Predictors of Left Atrial Thrombus Prior to Catheter Ablation of Atrial Fibrillation
SCHERR, D., DALAL, D., CHILUKURI, K., DONG, J., SPRAGG, D., HENRIKSON, C. A., NAZARIAN, S., CHENG, A., BERGER, R. D., ABRAHAM, T. P., et al. (2009) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01336.x · Cited by 187
PRAGST, I., ZEITLER, S. H., DOERR, B., KASPEREIT, F. J., HERZOG, E., DICKNEITE, G., & van RYN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04859.x · Cited by 186
Sié, P., Samama, C. M., Godier, A., Rosencher, N., Steib, A., Llau, J. V., Van der Linden, P., Pernod, G., Lecompte, T., Gouin-Thibault, I., et al. (2011) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2011.09.001 · Cited by 183
Boriani, G., Savelieva, I., Dan, G.-A., Deharo, J. C., Ferro, C., Israel, C. W., Lane, D. A., La Manna, G., Morton, J., Mitjans, A. M., et al. (2015) · EP Europace · doi:10.1093/europace/euv202 · Cited by 182
Lakkireddy, D., Reddy, Y. M., Di Biase, L., Vallakati, A., Mansour, M. C., Santangeli, P., Gangireddy, S., Swarup, V., Chalhoub, F., Atkins, D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.039 · Cited by 177
Katholing, A., Wallenhorst, C., Freedman, S. B., & Martinez, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0350 · Cited by 173
Rådberg, J. A., Olsson, J. E., & Rådberg, C. T. (1991) · Stroke · doi:10.1161/01.str.22.5.571 · Cited by 172
Vrijens, B., & Heidbuchel, H. (2015) · Europace · doi:10.1093/europace/euu311 · Cited by 172
Self-citationBleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
LEVI, M., EERENBERG, E., & KAMPHUISEN, P. W. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04432.x · Cited by 170
What is ‘valvular’ atrial fibrillation? A reappraisal
De Caterina, R., & Camm, A. J. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu352 · Cited by 164
Self-citationBassiouny, M., Saliba, W., Rickard, J., Shao, M., Sey, A., Diab, M., Martin, D. O., Hussein, A., Khoury, M., Abi-Saleh, B., et al. (2013) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.113.000320 · Cited by 164
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2014) · EP Europace · doi:10.1093/europace/euu208 · Cited by 164
Self-citationEffect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
Wang, X., Mondal, S. A., Wang, J. J. J., Tirucherai, G., Zhang, D., Boyd, R. A., & Frost, C. E. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0055-y · Cited by 162
Frost, C. E., Byon, W., Song, Y., Wang, J., Schuster, A. E., Boyd, R. A., Zhang, D., Yu, Z., Dias, C., Shenker, A., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12541 · Cited by 160
Assays for Measuring Rivaroxaban: Their Suitability and Limitations
Lindhoff-Last, E., Samama, M. M., Ortel, T. L., Weitz, J. I., & Spiro, T. E. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181f2f264 · Cited by 159
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer
Goldhaber, S. Z., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Hantel, S., Feuring, M., Kreuzer, J., & Schulman, S. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0977 · Cited by 159
Hecker, J., Marten, S., Keller, L., Helmert, S., Michalski, F., Werth, S., Sahin, K., Tittl, L., & Beyer-Westendorf, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-10-0840 · Cited by 159
Di Biase, L., Lakkireddy, D., Trivedi, C., Deneke, T., Martinek, M., Mohanty, S., Mohanty, P., Prakash, S., Bai, R., Reddy, M., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.02.028 · Cited by 158
Alexander, J. H., Lópes, R. D., Thomas, L. E., Alings, M., Atar, D., Aylward, P. E., Goto, S., Hanna, M., Huber, K., Husted, S., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht445 · Cited by 157
Self-citationDose-Finding Study of Rivaroxaban in Hemodialysis Patients
Vriese, A. S. D., Caluwé, R., Bailleul, E., Bacquer, D. D., Borrey, D., Vlem, B. V., Vandecasteele, S. J., & Emmerechts, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.01.022 · Cited by 154
Matsushima, N., Lee, F., Sato, T., Weiss, D., & Mendell, J. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.53 · Cited by 153
Lópes, R. D., Elliott, L. E., White, H. D., Hochman, J. S., de Werf, F. V., Ardissino, D., Nielsen, T. T., Weaver, W. D., Widimský, P., Armstrong, P. W., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp213 · Cited by 150
Mendell, J., Kastrissios, H., GREEN, M. L., Carrothers, T. J., Song, S., Patel, I. J., Antman, E. M., Giugliano, R. P., Kunitada, S., Dornseif, B. E., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0566 · Cited by 150
Gorst‐Rasmussen, A., Skjøth, F., Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Lane, D. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12845 · Cited by 149
Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH
Barnes, G. D., Ageno, W., Ansell, J., & Kaatz, S. S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12969 · Cited by 147
Beyer-Westendorf, J., Förster, K., Ebertz, F., Gelbricht, V., Schreier, T., Gobelt, M., Michalski, F., Endig, H., Şahin, K., Tittl, L., et al. (2015) · EP Europace · doi:10.1093/europace/euu319 · Cited by 147
Hansen, M. L., Jepsen, R. M. H. G., Olesen, J. B., Ruwald, M. H., Karasoy, D., Gislason, G., Hansen, J., Køber, L., Husted, S., & Torp-Pedersen, C. T. (2014) · EP Europace · doi:10.1093/europace/euu189 · Cited by 145
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
Caterina, R. D., Andreotti, F., Arnesen, H., Bachmann, F., Huber, K., Jespersen, J., Kristensen, S. D., Lip, G. Y. H., Morais, J., Rasmussen, L., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0228 · Cited by 144
Lane, D. A., Aguinaga, L., Blomström-Lundqvist, C., Boriani, G., Dan, G.-A., Hills, M. T., Hylek, E. M., LaHaye, S. A., Lip, G. Y. H., Lobban, T., et al. (2015) · Europace · doi:10.1093/europace/euv233 · Cited by 142
Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation
Ebertz, F., Förster, K., Gelbricht, V., Michalski, F., Köhler, C. U., Werth, S., Endig, H., Pannach, S., Tittl, L., Şahin, K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0954 · Cited by 139
Escolar, G., Fernandez‐Gallego, V., Arellano‐Rodrigo, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078696 · Cited by 135
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614550583 · Cited by 134
Self-citationOral anticoagulation in surgical procedures: risks and recommendations
Torn, M., & Rosendaal, F. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04652.x · Cited by 132
Marbury, T. C., Matsushima, N., Chen, S., Wickremasingha, P. K., He, L., Dishy, V., Brown, K. S., & Parasrampuria, D. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0547 · Cited by 128
Laliberté, F., Nelson, W. W., Lefèbvre, P., Schein, J. R., Rondeau-Leclaire, J., & Duh, M. S. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0040-x · Cited by 122
Kirchhof, P. F., Bax, J. J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosío, F. G., Crijns, H. J. G. M., Diener, H., Goette, A., et al. (2009) · EP Europace · doi:10.1093/europace/eup124 · Cited by 122
Self-citationDecrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin
Härtter, S., Koenen‐Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., & Reilly, P. A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04218.x · Cited by 120
Lip, G. Y. H., Haguenoer, K., Saint-Etienne, C., & Fauchier, L. (2014) · Chest · doi:10.1378/chest.13-2976 · Cited by 120
McCready, J. W., Nunn, L. M., Lambiase, P. D., Ahsan, S., Segal, O. R., Rowland, E., LOWE, M. D., & CHOW, A. W. C. (2010) · EP Europace · doi:10.1093/europace/euq074 · Cited by 118
Mendell, J., Tachibana, M., Shi, M., & Kunitada, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010370974 · Cited by 117
Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment
Karjalainen, P. P., Vikman, S., Niemela, M. R., Porela, P., Ylitalo, A., Vaittinen, M.-A., Puurunen, M. K., Airaksinen, T. J., Nyman, K., Vahlberg, T. J., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn099 · Cited by 109
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation
Flaker, G., Lópes, R. D., Hylek, E. M., WOJDYLA, D. M., Thomas, L. E., Al‐Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D. A., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.967 · Cited by 106
Clemens, A., Noack, H., Ferreira, J., Connolly, S. J., Yusuf, S., & Lip, G. Y. H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0734 · Cited by 106
Rene, A. G., Généreux, P., Ezekowitz, M. D., Kirtane, A. J., Xu, K., Mehran, R., Brener, S. J., & Stone, G. W. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.09.016 · Cited by 105
Gibson, C. M., Chakrabarti, A. K., Mega, J. L., Bode, C., Bassand, J., Verheugt, F. W. A., Bhatt, D. L., Goto, S., Cohen, M. C., Mohanavelu, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.041 · Cited by 103
Nielsen, P. B., Lane, D. A., Rasmussen, L. H., Lip, G. Y. H., & Larsen, T. B. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0797-9 · Cited by 98
Coadministration of Dabigatran Etexilate and Atorvastatin
Stangier, J., Rathgen, K., Stähle, H., Reseski, K., Körnicke, T., & Roth, W. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256595 · Cited by 96
Rubboli, A., Schlitt, A., Kiviniemi, T., Biancari, F., Karjalainen, P., Valencia, J., Laine, M., Kirchhof, P., Niemelä, M., Vikman, S., et al. (2014) · Clinical Cardiology · doi:10.1002/clc.22254 · Cited by 95
Self-citationHonickel, M., Treutler, S., van Ryn, J., Tillmann, S., Rossaint, R., & Grottke, O. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-08-0712 · Cited by 95
Hohnloser, S. H., & Camm, A. J. (2013) · EP Europace · doi:10.1093/europace/eut241 · Cited by 93
Self-citationBerti, D., Hendriks, J., Brandes, A., Deaton, C., Crijns, H. J. G. M., Camm, A. J., Hindricks, G., Moons, P., & Heidbüchel, H. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht096 · Cited by 90
Self-citationInterpretation of Point-of-care INR Results in Patients Treated with Dabigatran
van Ryn, J., Baruch, L., & Clemens, A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.017 · Cited by 83
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01118-9 · Cited by 83
Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbüchel, H., Camm, A. J., Antman, E. M., & Ruff, C. T. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv201 · Cited by 81
Self-citationProvidencia, R. A., Albenque, J., Combes, S., Bouzeman, A., Casteigt, B. J., Combes, N., Narayanan, K., Marijon, É., & Bovéda, S. (2013) · Heart · doi:10.1136/heartjnl-2013-304386 · Cited by 78
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Enriquez, A. A., Lip, G. Y. H., & Baranchuk, A. M. (2015) · EP Europace · doi:10.1093/europace/euv030 · Cited by 76
Adherence and dosing frequency of common medications for cardiovascular patients.
Bae, J. P., Dobesh, P. P., Klepser, D. G., Anderson, J. D., Zagar, A. J., McCollam, P. L., & Tomlin, M. E. (2012) · PubMed · Cited by 75
Safe Use of Hemodialysis for Dabigatran Removal before Cardiac Surgery
Wanek, M. R., Horn, E. T., Elapavaluru, S., et al. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r081 · Cited by 74
Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage
Horstmann, S., Zugck, C., Krumsdorf, U., Rizos, T., Rauch, G., Geis, N. A., Hardt, S. E., & Veltkamp, R. C. (2013) · Neurology · doi:10.1212/wnl.0000000000000022 · Cited by 72
Granger, C. B., Lópes, R. D., Hanna, M., Ansell, J., Hylek, E. M., Alexander, J. H., Thomas, L. E., Wang, J., Bahit, M. C., Verheugt, F. W. A., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.09.006 · Cited by 70
Glund, S., Stangier, J., Schmohl, M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.344.344 · Cited by 70
Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned?
Hankey, G. J. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0480-9 · Cited by 69
Research works printed but not linked: 23
- 10.1160/TH14-06-0564 · doi:10.1160/th14-06-0564
- 10.1016/S0735-1097(14)60325-9 · doi:10.1016/s0735-1097(14)60325-9
- Matsushima N Lee F Sato T Weiss D Mendell J . Absolute Bioavailability of Edoxaban in Healthy Subjects. The AAPS Journal 2011;13 (Suppl):S2. (abstract).
- Frost C Yu Z Nepal S Bragat A Moore K Shenker A Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008;48:1132 (abstract).
- Vakkalagadda B Frost C Wang J Nepal S Schuster A Zhang D Effect of rifampicin on the pharmacokinetics of apixaban, on oral direct inhibitor of factor Xa. J Clin Pharmacol 2009;49:1124 (abstract).
- Frost C Boyd RA . The contribution of apixaban renal clearance to total clearance. J Thromb Thrombolysis 2015; doi:10.1007/s11239-015-1220-8 doi:10.1007/s11239-015-1220-8. · doi:10.1007/s11239-015-1220-8
- Kubitza D Becka M Zuehlsdorf M Mueck W . No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006;46:702 (Abstract 11). · DOI · Paper page
- 10.1111/bcp.12075 · DOI · Paper page
- 10.1124/dmd.113.053769 · doi:10.1124/dmd.113.053769
- Mendell J Noveck R Zahir H Lee F Petrushin V Rubets I The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin Pharmacol Toxicol 2010;107:2848. (Abstract).
- Pan X Kachroo S Liu X Kawabata H Phatak H . Discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tale of first 200 days. Eur Heart J 2014;35 (Abstract Supplement):897. · doi:10.1016/s0735-1097(14)60415-0
- Chang M Shenker A Wang J Yu Z Pursley J Boyd R Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 2012;1:185.
- Ridout G de la Motte S Niemczyk S Sramek P Johnson L Jin J Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model. J Clin Pharmacol 2009;49:1124. (abstract).
- 10.1016/j.cjca.2014.01.015 · doi:10.1016/j.cjca.2014.01.015
- Wang X Tirucherai G Ehlgen A Wang J Chang M Zhang D Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev 2012;1:187.
- Perlstein I Wang Z Song Y Wang J Bedford B Chang M Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects. Blood 2014;124:345. · doi:10.1182/blood.v124.21.345.345
- 10.1093/europace/eut296 · doi:10.1093/europace/eut296
- 10.1093/europace/eut353 · doi:10.1093/europace/eut353
- 10.1016/j.amjcard.2012.12.046 · DOI
- Jennings JM Robichaux R McElderry HT Plumb VJ Gunter A Doppalapudi H Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol 2013;24:1125–9. · doi:10.1111/jce.12214
- 10.1093/europace/eut423 · doi:10.1093/europace/eut423
- 10.1007/s003920050171 · doi:10.1007/s003920050171
- 10.1016/j.ahj.2014.12.020 · DOI
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citation2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Metadata
- Authors
- Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P.
- Venue
- Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-31
- Volume
- 17
- Issue
- 10
- Pages
- 1467-1507
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W1834574045
- Cited by
- 1,113
- References
- 241
- FWCI
- 151.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Bayer Pharma AG
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Pfizer Alliance and Daiichi-Sankyo Europe
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.